SBL Infratech is a real estate development and trading company that builds residential and commercial projects, primarily in Rajasthan, and trades in various commodities including FMCG items.
The company operates in a highly fragmented and cyclical industry with no evidence of brand power, cost advantage, or high switching costs. Financial metrics show low net margins (3.3%) and a lack of consistent revenue from core operations, indicating a commodity-like business profile.
Management has shifted capital between real estate development and commodity trading. Recent years show significant investments in 'other loans and advances' and 'other non-current assets' rather than active project construction, resulting in poor cash conversion.
The investment collapsed as the company's lack of focus led to a total erosion of capital. Management's pivot from real estate to commodity trading and agricultural activities proved to be a value-destructive distraction. The massive 'Other Loans and Advances' were never recovered, revealing them to be disguised capital outflows rather than productive assets. As governance crumbled with the exit of multiple directors and auditors, the reported profits—which never turned into actual cash—evaporated, leaving shareholders with a shell of a business that lacked any core operational competency.
RichFakir rates SBL Infratech Ltd's business quality as mediocre — 50/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, SBL Infratech Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on SBL Infratech Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of SBL Infratech Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →